Search results
Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial. Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens.
28 lip 2024 · A new guideline by the American Society of Clinical Oncology (ASCO) encourages clinicians to talk openly and without judgment to adult patients with cancer about their use of or interest in using cannabis and cannabinoids. 1 This key overarching good practice statement in the guidelines frames the tenor in which clinicians should engage with ...
13 mar 2024 · Clinicians should recommend against use of cannabis and/or cannabinoids in place of cancer-directed treatment (Type: Informal consensus; Evidence quality: Very low; Strength of recommendation: Strong).
31 maj 2024 · Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
22 lut 2022 · To assess the efficacy, tolerability and safety of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer.
6 mar 2023 · The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.
We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients.
